In November 2025, the WHO Regional Director for the Western Pacific, himself a Tongan physician, published a rare personal account of an antibiotic access failure in Tonga.
He described a child brought to a provincial hospital with sepsis. Every antibiotic available was tried. None worked.
The child did not survive. This was not a story of drug resistance alone.
It was a story of supply gap, diagnostic absence, and a medicine procurement system that cannot guarantee the antibiotic on the shelf matches the pathogen in the patient.
In 2023, Tonga’s pharmaceutical imports reached an all-time high of 1,243,566 USD[1], confirming a strong positive trend.
This blog analyses which antibiotics Tonga needs most, where the supply gaps are, and what an API exporter must understand before positioning to serve this market.
Tonga’s Health System and the Antibiotic Demand Foundation
Tonga’s health infrastructure is small, centralised, and entirely import-dependent, making antibiotics the single most clinically critical pharmaceutical category the country procures.
Tonga at a Glance – The Health and Economic Context
The Kingdom of Tonga is a Polynesian monarchy of approximately 104,175 people (2024)[2], spread across 176 islands in the South Pacific, 36 of which are inhabited.
GDP stands at USD 616 million (2026 estimate),[2] with GDP per capita of USD 6,221 and real GDP growth of 2.3%. Tonga is classified as an upper-middle-income economy.
Health services are delivered through the National Referral Hospital at Vaiola (Tongatapu), three district hospitals, Prince Wellington Ngu’s (Vava’u), Princess Fusipala (Ha’apai), and Niu’eki (‘Eua), plus 14 health centres and 29 maternal and child health clinics across six island health districts.
| Indicator | Value |
| Population | 104,175 (2024) |
| GDP | USD 616 million (2026) |
| GDP per capita | USD 6,221 |
| Real GDP growth | 2.3% |
| Life expectancy | 72.9 years |
| MoH staff | 1,143 (June 2021) |
Health delivery organised under the Package of Essential Health Services (PEHS) framework, every medicine on the national formulary, including every antibiotic, must be imported.
Tonga’s Dual Disease Burden – Why Antibiotics Are the Single Most Critical API Category
Tonga faces a documented dual burden: rising non-communicable diseases (NCDs) combined with persistent communicable diseases.
In 2023, 633 people died from NCDs[3] and 76.1 from communicable diseases, with 24 deaths in children under five.
Four demand drivers define the antibiotic demand in Tonga:
WHO AMR National Action Plan – Tonga’s Active Antibiotic Stewardship Context
In Tonga, antimicrobial resistance (AMR) is an urgent policy concern, not a theoretical problem, as AMR is the term for microorganisms developing the ability to withstand conventional antimicrobials.
In 2024, WHO worked directly with Tonga to update and implement that country’s AMR National Action Plan (NAP) and AMR surveillance and antimicrobial stewardship programs.
WHO conducted a Joint External Evaluation (JEE) of Tonga in 2024.
Tonga is one of only four countries in the Western Pacific Region where a JEE was conducted that year.
This creates a structural demand from the WHO AWaRe (Access, Watch, Reserve) classification system.
At the procurement level for first-line treatments of common infections with low AMR risk, antibiotics fall within the Access group and have low procurement risk for Tonga.
For the 2024 WHO UNGA AMR declaration, the Access group antibiotics will account for 70% of human antimicrobial consumption by 2030.
This means for the forecasted 2025-2026 pharmaceutical Active Pharmaceutical Ingredient (API) imports to Tonga, there will be a more orderly and greater call for amoxicillin, ampicillin, co-trimoxazole, and benzylpenicillin.
| Micro-summary: With a dual burden of NCDs and communicable diseases and a 100% import-dependent pharmaceutical market, Tonga is a WHO AMR stewardship and procurement policy-focused country. Access group antibiotics will dominate procurement in a market where AMR worsens. Let’s now address the six major barriers this market faces. |
Six Barriers That Create Tonga’s Antibiotic API Supply Gap
Tonga’s antibiotic supply gap is the cumulative product of six documented structural barriers collectively explaining why this market remains chronically underserved and commercially open.
Barrier One – No Domestic API Manufacturing: 100% Import Dependency
Tonga has no pharmaceutical manufacturing capability.
Every antibiotic dispensed at Vaiola Hospital Tonga or a rural health centre in Ha’apai is imported.
The Central Medical Store (CMS) at Vaiola Hospital campus is the single procurement, storage, and distribution hub for all six island health districts, a single-point-of-failure vulnerability.
Given Tonga’s small import volume (USD 1.21 million in 2023),[1] most large international suppliers do not prioritise Tonga, leaving procurement to regional intermediaries at mark-up prices.
Barrier Two – Empirical Prescribing Without Diagnostics Drives AMR and Complicates Procurement Planning
WHO Regional Director Dr Saia Ma’u Piukala (November 2025): “In Tonga, health workers in rural clinics lack access to microbiological testing and even antibiotics, forcing reliance on empirical and sometimes inappropriate use of antibiotics.”
Without culture sensitivity testing, AMR is generated; without confirmed diagnosis data, evidence-based procurement planning is structurally impossible.
Barrier Three – Small Market Volume Makes Tonga Commercially Unattractive to Large Suppliers
India is Tonga’s leading pharmaceutical supplier, exporting USD 573,950[4] in pharmaceuticals in 2023. The UK exported USD 26,810[5] in 2023..
For large international suppliers, USD 1.21 million in total annual imports falls below minimum order viability, leaving Tonga chronically dependent on intermediaries.
Barrier Four – Zone IVb Stability Data Requirement Filters Poorly Prepared Suppliers
ICH Q1A Zone IVb testing requires products to demonstrate stability at 30°C ± 2°C and 65% RH ± 5% RH, the standard for tropical climates.
Many antibiotic products supplied to Tonga through indirect channels carry only Zone II (25°C/60% RH) stability data, insufficient for Tonga’s conditions.
Barrier Five – Remote Island Distribution Creates Last-Mile Medicine Access Failure
Beyond Tongatapu, Tonga’s outer islands Ha’apai, Vava’u, ‘Eua, Niuafo’ou, and Niuatoputapu are served by sporadic inter-island shipping and light aircraft.
WHO (2024) explicitly identifies Tonga as a country where health facilities are vulnerable to climate disruptions that cut off access to essential health services.
The Western Pacific experiences sea-level rises three to four times higher than the global average.
Barrier Six – Regulatory Framework Depends on New Zealand TGA-Like Recognition, Not a Standalone System
Tonga operates under the Tonga medicine import regulatory framework – the Tonga Medical Act, with practical reliance on TGA (Australia) and Medsafe (New Zealand) product registrations as quality proxies.
TGA or Medsafe finished-product registration is the strongest quality signal for Tonga MoH procurement.
| Micro-summary: Six barriers- zero domestic manufacturing, diagnostic opacity, sub-commercial market size, Zone IVb instability risk, last-mile logistics failure, and regulatory proxy dependence are not deterrents. They are the commercial case for why a prepared, compliant Indian API supplier can enter an underserved market. Now let’s map the specific APIs in demand. |
Most Demanded Antibiotic APIs in Tonga: The Market Gap Matrix
The WHO AWaRe framework maps directly to Tonga’s procurement priorities, and the following matrix identifies the ten most-in-demand antibiotic APIs, ranked by supply gap severity.
The WHO AWaRe classification organises antibiotics by AMR risk and clinical importance.
Under WHO WPRO guidance, Tonga’s Ministry of Health is shifting procurement toward Access group antibiotics to meet the 2030 target of 70% Access consumption.
This creates growing, predictable demand for a specific set of molecules aligned with India’s WHO-GMP API manufacturing strengths.
| Antibiotic API | AWaRe Category | Primary Indication in Tonga | Supply Gap | Stability Challenge |
| Amoxicillin (trihydrate/sodium) | Access – Priority | RTIs, skin/soft tissue infections, otitis media, dental infections | HIGH | Zone IVb moisture-sensitivity – humidity-resistant packaging required |
| Ampicillin sodium | Access | Inpatient respiratory infections, paediatric meningitis, sepsis, UTIs | HIGH | Cold chain for reconstituted solution; powder stable if sealed |
| Co-trimoxazole (SMX+TMP) | Access | UTIs, respiratory infections, PCP prophylaxis (HIV patients), diarrhoeal disease | MEDIUM-HIGH | Zone IVb tablet – well-characterised; standard packaging adequate |
| Benzylpenicillin (Penicillin G) | Access | Gonorrhoea (STI burden), streptococcal infections, rheumatic fever, syphilis | HIGH | Injectable only; cold chain; reconstituted stability hours only |
| Metronidazole | Access | Anaerobic infections, dental, surgical prophylaxis, Trichomonas (STI) | MEDIUM | Zone IVb tablet stable; IV requires temperature management |
| Gentamicin sulphate | Access | Neonatal sepsis, gram-negative infections, surgical prophylaxis | HIGH (injectable) | Cold chain required; WHO storage below 25°C – Zone IVb challenge |
| Doxycycline hyclate | Access | Chlamydia (STI), atypical RTIs, leptospirosis, scrub typhus | MEDIUM | Zone IVb photostability – dark packaging; moisture-sensitive capsule |
| Azithromycin dihydrate | Watch – restricted | Chlamydia, CAP, upper RTIs – empirical use continues despite Watch status | MEDIUM | Zone IVb tablet stable; suspension requires refrigeration post-reconstitution |
| Ceftriaxone sodium | Watch | Serious gram-negative infections, gonorrhoea (last-resort), meningitis | MEDIUM | Cold chain for reconstituted IV – major outer island logistics challenge |
| Erythromycin stearate | Access | Penicillin-allergy respiratory infections, streptococcal infections | MEDIUM-LOW | Zone IVb – moisture and acid-sensitive; enteric coating critical |
The three highest-priority APIs by supply gap severity are amoxicillin, ampicillin sodium, and benzylpenicillin.
All Access group molecules are directly aligned with Tonga’s AMR NAP priorities, and all within India’s established WHO-GMP API manufacturing capability.
| Micro-summary: Ten antibiotic APIs map to Tonga’s disease burden. Seven are WHO AWaRe Access groups. Three carry HIGH supply gap ratings. All require WHO-GMP certification and ICH Q1A Zone IVb stability data. Now it is time to go deep into compliance documentation requirements. |
What Documentation Tonga Requires for Antibiotic API Imports
Tonga’s import compliance framework is proxy-regulatory, but documentation standards are rigorous, and Zone IVb stability data is non-negotiable for all antibiotic API procurement.
WHO-GMP (World Health Organization Good Manufacturing Practice) is the minimum quality standard for pharmaceutical API and finished-dose manufacturing accepted by Tonga’s government procurement authorities and donor agencies.
| Buyer Type | GMP Requirement | Minimum Documentation | Stability Data | Regulatory Proxy | Priority Risk |
| Tonga MoH / CMS (public tender) | WHO-GMP minimum; TGA/Medsafe finished-product registration strengthens bid | CoA, GMP cert, CoO, MSDS/SDS, Zone IVb stability data, product specification | ICH Q1A Zone IVb (30°C/65%RH) MANDATORY | TGA (Australia) or Medsafe (NZ) | CMS tender quantification inaccuracies — use buffer stock guidance |
| WHO/UNICEF/ADB donor-funded | WHO-GMP; WHO-PQ preferred for some donor categories | As above + donor programme-specific dossier | Zone IVb mandatory | WHO-PQ — India’s ~57% WHO-PQ API coverage is a competitive advantage | Donor eligibility conditions vary — verify per-grant before tender |
| Private sector pharmacy (Nuku’alofa) | WHO-GMP accepted | CoA, GMP cert, MSDS — import declaration via Ministry of Revenue and Customs | Zone IVb recommended | TGA/Medsafe provides confidence | Commercially negligible volume — focus on public/donor channels |
The single most critical compliance point: ICH Q1A Zone IVb stability data is mandatory.
Suppliers submitting only Zone II (temperate-market) stability data will be disqualified from Tonga MoH procurement regardless of price competitiveness.
India’s ~57% WHO-PQ API list coverage is a direct commercial advantage for donor-funded procurement channels where WHO-PQ is preferred.
After understanding the compliance framework, it is time to look for the practical supply chain strategy for exports to Tonga.
How to Reach Tonga’s Antibiotic Market from India
To supply antibiotic API from India to Tonga requires a two-legged supply chain with specialist cold chain logistics and a distributor strategy in the Pacific, and built around current CMS partnerships in New Zealand and/or Australia.
Shipping Route: India → Tonga
Distributor / Partner Strategy for the Tonga Market
Comparison: Entry Route Options for the Tonga Antibiotic API Market
| Approach | Speed to Market | Cost | Best For |
| Direct-to-Ministry (CMS tender) | 6–18 months | Lower unit cost | Established exporters with WHO-PQ |
| New Zealand distributor partnership | 3–9 months | Higher unit cost (NZ margin) | New-to-market exporters |
| UNICEF/WHO procurement channel | Donor programme timeline | WHO reference pricing | WHO-GMP + WHO-PQ certified exporters |
| World Bank P180965 tender (DG Market) | Variable — active 2025 | Competitive | Suppliers ready to respond to live tenders |
Four channels are commercially relevant:
Now that the route-to-market is mapped, let’s assess the antibiotic API market outlook for Tonga through 2030.
Tonga Antibiotic API Market Outlook 2026-2030
Tonga’s antibiotic procurement market between now and 2030 is driven by four areas of demand.
These areas create a positive outlook primarily for Indian API exporters with a solid market presence and those who are compliant.
Demand Growth Drivers for Antibiotic APIs in Tonga 2026-2030
Risk-Adjusted Scenarios for Antibiotic API Exporters Targeting Tonga
| Scenario | Conditions | Market Impact | Recommended Strategy |
| Optimistic (2026–2028) | WHO AMR NAP fully implemented; World Bank P180965 disburses fully; donor funding increases; imports grow to USD 2–2.5 million | Structured multi-year Access group contracts; AWaRe-aligned tendering | Register with Tonga MoH; finalise Zone IVb documentation; partner with NZ distributor now |
| Base Case (2026–2028) | Gradual AMR NAP progress; ~8% YoY import growth continues | Small, growing market via NZ/AUS distributors; donor-funded tenders | NZ distributor partnership; UNICEF catalogue registration; monitor DG Market for P180965 tenders |
| Pessimistic (2027) | Category 5 cyclone damages CMS warehouse; emergency procurement triggered | Spot buying at premium; airfreight opportunity | Pre-cleared documentation; airfreight contingency emergency capability is a Pacific market differentiator |
| Micro-summary: The India-to-Tonga supply chain runs through Auckland. The fastest market entry is a New Zealand distributor partnership. The 2026-2030 outlook is structurally positive: World Bank investment, WHO AMR NAP implementation, and NCD-driven antibiotic demand will collectively expand Tonga’s pharmaceutical procurement market above its current baseline. |
Frequently Asked Questions
Q: Which antibiotic APIs are most in demand in Tonga?
The highest-demand antibiotic APIs in Tonga, ranked by supply gap severity, are amoxicillin, ampicillin sodium, Benzylpenicillin/Penicillin G, and gentamicin sulphate.
Co-trimoxazole, metronidazole, doxycycline, azithromycin, ceftriaxone, and erythromycin complete the demand matrix.
All conform to both the procurement focus areas in the Tonga AMR National Action Plan and the WHO AWaRe Access group framework.
Q: How large is the pharmaceutical import market in Tonga?
In 2023, Tonga’s pharmaceutical imports reached USD 1,214,121 an 8.4% increase from USD 1,119,894 in 2022, and an all-time high outside the 2021 COVID period. On the other hand, the long-run average (1995-2023) was USD 416,699.
While small in absolute terms, the market is growing, donor-funded procurement supplements the baseline, and the World Bank P180965 health project adds pharmaceutical procurement volume outside standard import channels.
Q: Does Tonga require a special product registration for antibiotic imports?
Tonga does not maintain a standalone product registration system. The Tonga medicine import regulatory framework uses TGA (Australia) and Medsafe (New Zealand) product registrations as de facto quality proxies.
For MoH/CMS procurement, the minimum documentation needed includes: a WHO-GMP Certificate, CoA, CoO, MSDS/SDS, and ICH Q1A Zone IVb stability data. Completed-dosage form registration with TGA or Medsafe provides the best procurement credentials with the Tonga Ministry of Health.
Q: What stability data must antibiotic APIs have for the Tonga market?
According to ICH Q1A, Zone IVb stability data for the conditions of 30°C ± 2°C and 65% ± 5% RH is a requirement. Data in Zone II (25°C/60% RH) for temperate markets will be considered inadequate for procurement in Tonga. Moisture and heat degradation of the beta-lactam group (amoxicillin, ampicillin and benzylpenicillin) and erythromycin will demand validated Zone IVb packaging.
Q: Is there a WHO AMR National Action Plan for Tonga and how does it affect antibiotic procurement?
Yes, the WHO worked with Tonga in 2024 on the Tonga AMR National Action Plan, antimicrobial use surveillance and stewardship programs, and arranged for a Joint External Evaluation that same year.
The NAP is systematically reorienting Tonga’s antibiotic procurement toward WHO AWaRe Access group molecules: amoxicillin, ampicillin, co-trimoxazole, benzylpenicillin, with a 70% Access consumption target by 2030.
This creates a predictable, growing demand signal in exactly the molecules India’s WHO-GMP API sector produces competitively.
Q: What is the best route for an Indian API exporter to supply antibiotics to Tonga?
For most Indian API exporters, the fastest commercially viable route is a New Zealand pharmaceutical distributor partnership. NZ distributors hold established CMS relationships, Pacific import clearance knowledge, and inter-island logistics arrangements.
Direct CMS tender registration yields better unit economics for multi-year contracts but takes 6-18 months. For donor-funded volumes, UNICEF Supply Catalogue registration and WHO-PQ certification for the finished-dose formulation partner are the qualifying prerequisites.
Exporters should also monitor DG Market for active World Bank P180965 tender notices.
Q: What documentation should an antibiotic API exporter prepare for Tonga procurement?
The minimum documentation package for a Tonga antibiotic API procurement submission: WHO-GMP certificate (current); Certificate of Analysis per batch; Certificate of Origin; MSDS/SDS; ICH Q1A Zone IVb stability data (30°C/65%RH); product specification; and DataLogger records for all cold-chain shipments.
For donor-funded procurement (UNICEF, WHO, ADB), include programme-specific dossiers and, where required, WHO Prequalification documentation. TGA or Medsafe finished-product registration significantly strengthens MoH procurement bids.
Conclusion
Tonga will never be a high-volume antibiotic API market. But it is a market where the stakes could not be higher, where a child in a provincial hospital dies because the right antibiotic was not available.
That is not an abstraction. It is documented testimony from the WHO’s own Regional Director, a Tongan physician who witnessed it firsthand.
The antibiotic API Tonga market gap is real, documented, and addressable by suppliers who come prepared with ICH Q1A Zone IVb stability data, WHO-GMP certification, Pacific-capable logistics, and the patience to build a supply relationship with a health system that needs reliability more than it needs the lowest price.
India is structurally positioned to fill this gap. The question is not whether the gap can be filled. It is which supplier comes prepared to fill it.
Actiza Pharmaceutical supplies WHO-GMP-certified antibiotic APIs including amoxicillin, ampicillin, gentamicin, co-trimoxazole, benzylpenicillin, metronidazole, and doxycycline to pharmaceutical companies serving Pacific Island markets.
Request our Pacific Antibiotic API Package:
WHO-GMP documentation, ICH Q1A Zone IVb stability data, cold chain shipping protocol, and competitive pricing for small-volume Pacific Island procurement quantities.
Contact Actiza Pharmaceutical to request your Pacific Antibiotic API Package today.
- https://www.ceicdata.com/en/indicator/tonga/imports-medicinal-and-pharmaceutical-product
- https://statisticsoftheworld.com/country/tonga
- https://ourworldindata.org/profile/health/tonga
- https://tradingeconomics.com/tonga/imports/india/pharmaceutical-products
- https://tradingeconomics.com/tonga/imports/united-kingdom/pharmaceutical-products
